This Article Abstract Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-06-1500v1 66/21/10269    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zakikhani, M. Articles by Pollak, M. Search for Related Content PubMed PubMed Citation Articles by Zakikhani, M. Articles by Pollak, M.

Metformin Is an AMP Kinase–Dependent Growth Inhibitor for Breast Cancer Cells

Departments of ¹ Oncology and ² Biochemistry, McGill University, Montreal, Quebec, Canada and ³ Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

Requests for reprints: Michael Pollak, Cancer Prevention Center, Jewish General Hospital, E-763, 3755 Cote Ste. Catherine Montreal, Quebec, Canada H3T 1E2. Phone: 514-340-8222, ext. 4139; Fax: 514-340-8600; E-mail: Michael.pollak{at}mcgill.ca.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Recent population studies provide clues that the use of metformin may be associated with reduced incidence and improved prognosis of certain cancers. This drug is widely used in the treatment of type 2 diabetes, where it is often referred to as an "insulin sensitizer" because it not only lowers blood glucose but also reduces the hyperinsulinemia associated with insulin resistance. As insulin and insulin-like growth factors stimulate proliferation of many normal and transformed cell types, agents that facilitate signaling through these receptors would be expected to enhance proliferation. We show here that metformin acts as a growth inhibitor rather than an insulin sensitizer for epithelial cells. Breast cancer cells can be protected against metformin-induced growth inhibition by small interfering RNA against AMP kinase. This shows that AMP kinase pathway activation by metformin, recently shown to be necessary for metformin inhibition of gluconeogenesis in hepatocytes, is also involved in metformin-induced growth inhibition of epithelial cells. The growth inhibition was associated with decreased mammalian target of rapamycin and S6 kinase activation and a general decrease in mRNA translation. These results provide evidence for a mechanism that may contribute to the antineoplastic effects of metformin suggested by recent population studies and justify further work to explore potential roles for activators of AMP kinase in cancer prevention and treatment. (Cancer Res 2006; 66(21): 10269-73)

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Metformin (1,1-dimethylbiguanide hydrochloride) is a biguanide commonly used in the treatment of type 2 diabetes mellitus (1). It is frequently referred to as an "insulin sensitizer" because in settings of insulin resistance and hyperinsulinemia, it lowers circulating insulin levels. There is some evidence that suggests that the mechanism of action of metformin involves enhancement of signaling through the insulin receptor, leading to improvement of insulin resistance, followed by reduction in insulin levels (2). However, recent work (3) provides evidence that the key action of metformin is the inhibition of hepatic glucose output by inhibition of gluconeogenesis, with a secondary decline in insulin levels, in the absence of a major effect on insulin signaling. There is strong evidence that in the liver, this mechanism involves the activation of AMP kinase via an LKB1-dependent mechanism (3, 4).

Although the molecular mechanisms of metformin have been studied in tissues such as liver, muscle, and fat, in relation to glucose homeostasis and insulin action, relatively little is known about the effects of this compound on epithelial tissues. This represents an important gap in knowledge, given that the recently described control system that links metformin to suppression of gluconeogenesis in hepatocytes involves activation of AMP kinase via LKB1. LKB1 was previously described as a tumor suppressor gene with relevance to epithelial neoplasia (5). Loss of function of LKB1 is associated with Peutz-Jeghers syndrome, which is characterized not only by multiple gastrointestinal polyps but also by a significantly increased lifetime risk (approaching 80%) of various epithelial cancers, including breast cancer (6). The molecular mechanism of action of LKB1, both as a regulator of gluconeogenesis in hepatocytes and more generally as a tumor suppressor gene in epithelial tissues, is thought to involve in large part its action as an activator of AMP kinase (ref. 3; reviewed in ref. 7). In general, physiologic activation of the AMP-activated protein kinase (AMPK) pathway by conditions of nutrient depletion down-regulates processes that consume energy, such as protein translation and cell division, and up-regulates those that generate energy.

Recent pilot studies carried out using population registries raise the possibility that metformin may reduce cancer risk and/or improve cancer prognosis. One showed an unexpectedly lower risk of a cancer diagnosis among diabetics using metformin compared with a control group of diabetics using other treatments (8); another showed lower cancer-specific mortality among subjects with diabetes using metformin compared with diabetics on other treatments (9).

There have been occasional reports of antineoplastic activity of metformin in various experimental models. However, the underlying mechanistic aspects have not been explored, and these observations might be related to uncharacterized direct actions of metformin on cancer cells or to indirect actions of the drug, such as reduction of insulin levels. Here, we describe in vitro experiments carried out to investigate the hypothesis that metformin exhibits direct antiproliferative actions on epithelial cells in vitro.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Chemicals. Cell culture materials were obtained from Invitrogen (Burlington, Ontario, Canada). Anti–phospho-specific (Thr¹⁷²) AMPK and anti-AMPK, anti–phospho-p70S6K (Thr³⁸⁹), anti–phospho-mammalian target of rapamycin (anti–phospho-mTOR; Ser²⁴⁴⁸), anti-mTOR, anti–phospho-specific S6 ribosomal protein (Ser^235/236), anti–phosphospecific acetyl-CoA carboxylase (Ser⁷⁹), and anti-ß-actin were purchased from Cell Signaling Technology (Beverly, MA). Anti-AMPK1 and anti-AMPK2 were purchased from Upstate (Charlottesville, VA). Horseradish peroxidase–conjugated anti-rabbit IgG, anti-mouse IgG, and enhanced chemiluminescence (ECL) reagents were from Pharmacia-Amersham (Baie d'Urfé, Quebec, Canada). Metformin was obtained from Sigma-Aldrich (St. Louis, MO). Small interfering RNA (siRNA) SMARTpool/AMPK1 was obtained from Upstate (Charlottesville, VA). Negative control siRNA (Alexa Fluor 488) was purchased from Qiagen (Mississauga, Ontario, Canada).

Cell lines and culture conditions. Cell lines were purchased from the American Type Culture Collection (Manassas, VA). Cells were cultured in RPM1 1640 (MCF-7, PC-3, SKOV3, and OVCAR3), DMEM (HeLa), or D-MEM/F12 with MEGM Single Quots (Cambrex, Walkersville MD; MCF10A) and supplemented with 10% fetal bovine serum (FBS) and 100 units/mL gentamicin at 37°C and 5% CO₂ in 75-cm² flasks. Cells were passaged by 0.25% Trypsin-EDTA when they reached 80% confluence.

Cell proliferation assay. The effect of metformin on cell lines was evaluated by the indicator dye Alamar Blue (Biosource International, Camarillo, CA). Cells were plated at 5 x 10³ per well in triplicate in 96-well plates and incubated in medium containing 10% FBS. After 24 hours, the complete medium was replaced with test medium containing vehicle control or various doses of metformin for 72 hours at 37°C. Alamar Blue was then added, and all plates were incubated at 37°C, and a colorimetric change was measured according to the methods provided by the supplier.

Protein extraction and Western blot analysis. Cells were washed thrice with ice-cold PBS and lysed in 100 to 400 µL lysis buffer [20 mmol/L Tris-HCl (pH 7.5)], 150 mmol/L NaCl, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L ß-glycerol phosphate, 1 mmol/L Na₃VO₄, 1 mmol/L EGTA, 1% Triton, and complete protease inhibitor mixture inhibitors (Roche, Mannheim, Germany). Cells debris was removed by centrifugation at 14,000 x g for 20 minutes at 4°C. Following assay for total protein (Bio-Rad, Mississauga, Ontario, Canada), clarified protein lysates from each experimental condition (40-50 µg) were boiled for 5 minutes and subjected to electrophoresis in denaturing 8% SDS-polyacrylamide gel for mTOR, or 10% SDS-PAGE for other proteins. After stripping the membranes with stripping buffer [62 mmol/L Tris-HCl (pH 6.8), 100 mmol/L ß-mercaptoethanol, 2% SDS], the membranes were probed with antibodies of interest. Horseradish peroxidase–conjugated anti-rabbit IgG and anti-mouse IgG were used as secondary antibodies. The position of proteins was visualized using the ECL reagent.

Cell transfection. MCF-7 cells were transfected with siRNA targeting the AMPK1 or a negative control siRNA using Oligofectamine (Invitrogen) as described by the manufacturer's instructions. Cells cultures were incubated for 24 hours with various concentrations of siRNA before metformin treatment.

[³⁵S]methionine metabolic labeling. MCF-7 cells (seeded in 24-well plates) were incubated with increasing doses of metformin for 24 hours in DMEM supplemented with 10% FBS. After 24 hours, cells were washed once with PBS and incubated with metformin in methionine-free DMEM without FBS for 2 hours. The medium was then replaced with methionine-free DMEM containing ³⁵S-protein labeling mix (20 µCi/mL). After 45 minutes, the cells were washed with cold PBS and lysed in buffer (described in Protein Extraction and Western Blot Analysis), and radioactivity incorporated into the TCA precipitable material was measured.

Statistical analysis. Before statistical analysis, data were square root transformed to satisfy the assumptions of analysis. Statistical significance was evaluated using GLM Procedure, Student Newman-Keuls test, with Statistical Analysis System software, version 8e (SAS Institute, Cary, NC), with Ps 0.05 considered significant.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Metformin acts as a growth inhibitor rather than an insulin sensitizer for MCF-7 human breast cancer cells. MCF-7 cells are known to be responsive to insulin and insulin-like growth factors (IGF), and this is confirmed by the data in Fig. 1A . However, metformin, rather than enhancing insulin or IGF-I-stimulated growth, acted as a growth inhibitor, an action correlated with a suppression of phosphorylation of p70S6K at Thr³⁸⁹ (Fig. 1B). To examine the effect of metformin on proliferation more generally, dose-response studies were carried out on several cell lines (Fig. 1C). Interestingly, several cancer cell lines, but not the LKB1^–/– HeLa cell line (10), were growth inhibited. Untransformed MCF-10A human breast epithelial cells were also growth inhibited.

View larger version (24K): [in this window] [in a new window]   Figure 1. Effects of metformin on insulin or IGF-stimulated proliferation of MCF-7 breast cancer cells under serum-free conditions and more generally on epithelial cell proliferation. A, MCF-7 cells were plated onto 96-well plates in culture medium containing 10% FBS. After 24 hours, serum-free medium containing metformin (10 mmol/L) alone or with IGF-1 (40 ng/mL) or insulin (5 µg/mL) were provided, and cells were incubated for 72 hours. Cell proliferation in each well was measured by Alamar Blue dye reduction. Columns, mean of two independent experiments carried out in triplicate (n = 6); bars, SE. *, P = 0.0359, difference between the IGF-I condition and IGF-I plus metformin condition; **, P = 0.0346, difference between the insulin condition and insulin plus metformin condition. B, MCF-7 cells were plated in culture medium containing 10% FBS. After 24 hours, serum-free medium was replaced and incubated for 16 hours. Starved cells were pretreated with vehicle or 40 ng/mL IGF-1 or 5 µg/mL insulin (Ins) for 30 minutes followed by adding 10 mmol/L metformin. Cells were incubated for 48 hours. Cell lysates were analyzed by Western blot for phosphorylation of p70S6K (Thr389). ß-Actin is shown as a loading control. C, growth inhibition of cancer cells MCF-7 (breast), PC-3 (prostate), and SKOV3 and OVCAR3 (ovary) was observed. Untransformed MCF-10A human breast epithelial cells were also growth inhibited. HeLa cells, which have no functional LKB1 allele, were not inhibited. Cells were seeded into 96-well plates in the presence of 1% FBS and after 24 hours treated with different concentrations of metformin. Cell proliferation in each well was measured by Alamar Blue dye reduction. Columns, mean from three independent experiments done in triplicate; bars, SE.

View larger version (12K): [in this window] [in a new window]   Figure 2. A, metformin activates AMPK and reduces p70S6K activation in MCF-7 cells. MCF-7 cells were treated with various doses of metformin for 72 hours. After harvesting, cells were lysed and prepared for immunoblot analysis using antibodies against phospho-AMPK (Thr172), phosphorylated (Ser2448) and non-phosphorylated mTOR, and phosphorylated (Thr389) p70S6K. ß-Actin is shown as a loading control. B, to determine if the AMP analogue AICAR has a similar effect to metformin, MCF-7 cells were treated with metformin or AICAR in the presence of 1% FBS for 72 hours. After harvesting, cells were lysed and prepared for immunoblot analysis using antibodies against phospho-AMPK (Thr172), phospho-mTOR (Ser2448), and phospho-p70S6K. ß-Actin is shown as a loading control.

siRNA against AMP kinase (1 subunit) rescues cells from metformin-induced growth inhibition.

View larger version (27K): [in this window] [in a new window]   Figure 3. AMPK1 siRNA reduces AMPK expression and rescues MCF-7 cells from the inhibitory effect of metformin. A, MCF-7 cells were transfected with 50 nmol/L AMPK1-siRNA or with control siRNA using Oligofectamine. Twenty-four hours after transfection, cells were treated with metformin for 48 hours. Cell proliferation in each well was measured by Alamar Blue dye reduction. Columns, mean of two independent experiments carried out in triplicate (n = 6); bars, SE. *, P = 0.0011, difference between the control and metformin conditions was significant; **, P = 0.0189, difference between siRNA-AMP kinase and siRNA-AMP kinase plus metformin. Percentage of cell proliferation relative to control. B, MCF-7 cells were transfected with 50 nmol/L AMPK1-siRNA or with control siRNA using Oligofectamine. Six hours after transfection, medium was changed to 1% FBS with or without metformin (5 mmol/L), and cells were incubated for 72 hours. After harvesting, cells were lysed and prepared for immunoblot analysis using antibodies against phospho-AMPK (Thr172), phospho-mTOR (Ser2448), AMPK, AMPK1, phospho-ACC (Ser79), phospho-p70S6K (Thr389), and phospho-S6 ribosomal protein (Ser235/236). ß-Actin is shown as a loading control.

Similar results were obtained with MCF-10A cells (data not shown).

Effect of metformin on mRNA translation. In view of the effect of metformin on mTOR and S6 kinase activation, we hypothesized that protein translation would be decreased by this drug in epithelial cells. Data in Fig. 4 support this hypothesis by showing a general decline in protein synthesis on exposure to growth inhibitory concentrations of metformin.

View larger version (8K): [in this window] [in a new window]   Figure 4. Inhibition of protein synthesis by metformin. MCF-7 cells were incubated with the indicated doses of metformin for 24 hours, and 35S methionine-protein labeling mix (20 µCi/mL) was added to the cells for 45 minutes. Cells were harvested after labeling, and radioactivity incorporated into the TCA precipitable material was measured. Protein synthesis levels are displayed as a percentage of that exhibited in the absence of metformin. The experiment was carried out three separate times. Points, mean; bars, SE. P = 0.0019, difference between protein synthesis in the absence of metformin and in the presence of 15 mmol/L metformin was significant.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

Data presented here show that activation of the AMPK pathway by metformin is not confined to hepatocytes but can be observed in epithelial cells as well. In epithelial cells, sequellae of pathway activation include reduced proliferation, an expected consequence of the observed reduction in mTOR activation, S6 kinase inactivation, and general reduction of mRNA translation and protein synthesis. Thus, the view that epithelial cells of organs such as breast, prostate, colon, and lung are "bystanders" unaffected by metformin treatment may be inaccurate. Indeed, the effects of metformin on these pathways in epithelial cells may be relevant to the recent preliminary observations from population studies suggesting that metformin administration reduces cancer risk (8) and mortality (9). Our data are consistent with prior observations (11) emphasizing that in tissue other than muscle and liver, the 1 isoform is physiologically more important than 2 isoform.

Antiproliferative actions of metformin on untransformed or transformed epithelial cells via AMP kinase–dependent pathways are in keeping with the role of AMP kinase as an energy sensor that down-regulates processes, such as protein synthesis, when energy is in short supply. Thus, by pharmacologically activating some of the intracellular control systems physiologically activated by nutrient deprivation, metformin acts as an inhibitor of proliferation. It is a classic experimental observation that severe dietary restriction protects rodents from a variety of carcinogenic influences (12). There is evidence (reviewed in ref. 13) that, at the level of whole-organism physiology, this protection is mediated at least in part by the suppressive effect of dietary restriction on the circulating level of IGF-I, which influences cancer risk (14). At the cellular level, physiologic or pharmacological activation of AMP kinase would serve to further attenuate signaling in networks downstream of insulin and/or IGF-I receptors, particularly at the level of mTOR (15).

Metformin is unlikely to directly affect those cancers that exhibit biallelic loss of function of LKB1 or other critical downstream signaling molecules, in keeping with our observation of lack of inhibition of LKB1 null HeLa cells shown in Fig. 1. Germ line homozygous loss of function of LKB1 is embryonic lethal (16); subjects with Peutz-Jeghers syndrome have a functional allele that may even be retained in some Peutz-Jeghers polyps and cancers. The possibility that metformin, by up-regulating activation of the retained functional LKB1 allele in halploinsufficent epithelial tissues, might attenuate manifestations of neoplasia in Peutz-Jeghers syndrome deserves investigation.

Further work is needed to determine the relative importance of direct (AMP kinase pathway activation) and indirect (reduction of insulin levels) mechanisms by which metformin may act as an antiproliferative agent for normal and/or transformed epithelial cells in vivo. The indirect mechanism may be of considerable importance in subjects with high insulin levels and/or cancers with high levels of insulin and/or hybrid insulin/IGF-I receptors (17, 18), where there is emerging evidence that ligand levels influence risk and prognosis (19, 20). However, the direct action of metformin as an activator of the LKB1/AMP kinase tumor suppressor pathway in epithelial cells reported here suggests the possibility of broader clinical relevance.

	Acknowledgments

 
Grant support: Translation Acceleration grant from the Canadian Breast Cancer Research Alliance and Terry Fox Foundation Research Studentship (R. Dowling).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4/25/06. Revised 8/15/06. Accepted 9/13/06.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Witters LA. The blooming of the French lilac. J Clin Invest 2001;108:1105–7.[CrossRef][Medline]
2. Holland W, Morrison T, Chang Y, et al. Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol 2004;67:2081–91.[CrossRef][Medline]
3. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642–6.[Abstract/Free Full Text]
4. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167–74.[CrossRef][Medline]
5. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184–7.[CrossRef][Medline]
6. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447–53.[CrossRef][Medline]
7. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15–25.[CrossRef][Medline]
8. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304–5.[Free Full Text]
9. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254–8.[Abstract/Free Full Text]
10. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004;101:3329–35.[Abstract/Free Full Text]
11. Stapleton D, Mitchelhill KI, Gao G, et al. Mammalian AMP-activated protein kinase subfamily. J Biol Chem 1996;271:611–4.[Abstract/Free Full Text]
12. Kritchevsky D, Klurfeld DM. Influence of caloric intake on experimental carcinogenesis: a review. Adv Exp Med Biol 1986;206:55–68.[Medline]
13. Hursting SD, Lavigne JA, Berrigan D, et al. Diet-gene interactions in p53-deficient mice: insulin-like growth factor-1 as a mechanistic target. J Nutr 2004;134:2482–6S.
14. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505–18.[CrossRef][Medline]
15. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6:91–9.[CrossRef][Medline]
16. Jishage K, Nezu J, Kawase Y, et al. Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis. Proc Natl Acad Sci U S A 2002;99:8903–8.[Abstract/Free Full Text]
17. Pandini G, Frasca F, Mineo R, et al. Insulin/insulin-like growth factor-I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002;277:39684–95.[Abstract/Free Full Text]
18. Sachdev D, Singh R, Fujita-Yamaguchi Y, et al. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006;66:2391–402.[Abstract/Free Full Text]
19. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002;20:42–51.[Abstract/Free Full Text]
20. Pollak M, Chapman J, Shepherd L, et al. Insulin resistance, estimated by serum c-peptide level, is associated with reduced event-free survival for postmenopausal women in the NCIC MA14 adjuvant breast cancer trial. J Clin Oncol 2006;24:524 (June 20 supplement).

This article has been cited by other articles:

				H. A. Hirsch, D. Iliopoulos, P. N. Tsichlis, and K. Struhl Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission Cancer Res., October 1, 2009; 69(19): 7507 - 7511. [Abstract] [Full Text] [PDF]

				M. E. Grossmann, N. K. Mizuno, M. L. Dammen, T. Schuster, A. Ray, and M. P. Cleary Eleostearic Acid Inhibits Breast Cancer Proliferation by Means of an Oxidation-Dependent Mechanism Cancer Prevention Research, October 1, 2009; 2(10): 879 - 886. [Abstract] [Full Text] [PDF]

				K. Kisfalvi, G. Eibl, J. Sinnett-Smith, and E. Rozengurt Metformin Disrupts Crosstalk between G Protein-Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth Cancer Res., August 15, 2009; 69(16): 6539 - 6545. [Abstract] [Full Text] [PDF]

				M. Pollak Macronutrient Intake and Cancer: How Does Dietary Restriction Influence Tumor Growth and Why Should We Care? Cancer Prevention Research, August 1, 2009; 2(8): 698 - 701. [Abstract] [Full Text] [PDF]

				S. Jiralerspong, S. L. Palla, S. H. Giordano, F. Meric-Bernstam, C. Liedtke, C. M. Barnett, L. Hsu, M.-C. Hung, G. N. Hortobagyi, and A. M. Gonzalez-Angulo Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer J. Clin. Oncol., July 10, 2009; 27(20): 3297 - 3302. [Abstract] [Full Text] [PDF]

				G. R. Steinberg and B. E. Kemp AMPK in Health and Disease Physiol Rev, July 1, 2009; 89(3): 1025 - 1078. [Abstract] [Full Text] [PDF]

				H. G. Woo, E. S. Park, J.-S. Lee, Y.-H. Lee, T. Ishikawa, Y. J. Kim, and S. S. Thorgeirsson Identification of Potential Driver Genes in Human Liver Carcinoma by Genomewide Screening Cancer Res., May 1, 2009; 69(9): 4059 - 4066. [Abstract] [Full Text] [PDF]

				J. R. Fay, V. Steele, and J. A. Crowell Energy Homeostasis and Cancer Prevention: The AMP-Activated Protein Kinase Cancer Prevention Research, April 1, 2009; 2(4): 301 - 309. [Abstract] [Full Text] [PDF]

				M. Cazzaniga, B. Bonanni, A. Guerrieri-Gonzaga, and A. Decensi Is it Time to Test Metformin in Breast Cancer Clinical Trials? Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 701 - 705. [Abstract] [Full Text] [PDF]

				A. Vazquez-Martin, C. Oliveras-Ferraros, S. del Barco, B. Martin-Castillo, and J. A. Menendez The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy Ann. Onc., March 1, 2009; 20(3): 592 - 595. [Full Text] [PDF]

				J. A. Menendez, A. Vazquez-Martin, F. J. Ortega, and J. M. Fernandez-Real Fatty Acid Synthase: Association with Insulin Resistance, Type 2 Diabetes, and Cancer Clin. Chem., March 1, 2009; 55(3): 425 - 438. [Abstract] [Full Text] [PDF]

				M. Javle, A. Abernethy, N. L. Busaidy, and J. H. Lee Dilemmas in Upper Gastrointestinal Cancers: Focus on Symptom Improvement ASCO Educational Book, January 1, 2009; 2009(1): 228 - 238. [Abstract] [Full Text] [PDF]

				Y. Li, P. Hao, S. Zheng, K. Tu, H. Fan, R. Zhu, G. Ding, C. Dong, C. Wang, X. Li, et al. Gene expression module-based chemical function similarity search Nucleic Acids Res., November 1, 2008; 36(20): e137 - e137. [Abstract] [Full Text] [PDF]

				J. M. Rosenbluth, D. J. Mays, M. F. Pino, L. J. Tang, and J. A. Pietenpol A Gene Signature-Based Approach Identifies mTOR as a Regulator of p73 Mol. Cell. Biol., October 1, 2008; 28(19): 5951 - 5964. [Abstract] [Full Text] [PDF]

				M. Zakikhani, R. J.O. Dowling, N. Sonenberg, and M. N. Pollak The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase Cancer Prevention Research, October 1, 2008; 1(5): 369 - 375. [Abstract] [Full Text] [PDF]

				J. H. Scarpello and H. C. Howlett Metformin therapy and clinical uses Diabetes and Vascular Disease Research, September 1, 2008; 5(3): 157 - 167. [Abstract] [PDF]

				C. Algire, M. Zakikhani, M.-J. Blouin, J. H. Shuai, and M. Pollak Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth Endocr. Relat. Cancer, September 1, 2008; 15(3): 833 - 839. [Abstract] [Full Text] [PDF]

				N. Turner, J.-Y. Li, A. Gosby, S. W.C. To, Z. Cheng, H. Miyoshi, M. M. Taketo, G. J. Cooney, E. W. Kraegen, D. E. James, et al. Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I: A Mechanism for the Action of Berberine to Activate AMP-Activated Protein Kinase and Improve Insulin Action Diabetes, May 1, 2008; 57(5): 1414 - 1418. [Abstract] [Full Text] [PDF]

				P. J. Goodwin Insulin in the Adjuvant Breast Cancer Setting: A Novel Therapeutic Target for Lifestyle and Pharmacologic Interventions? J. Clin. Oncol., February 20, 2008; 26(6): 833 - 834. [Full Text] [PDF]

				Y. D. Kim, K.-G. Park, Y.-S. Lee, Y.-Y. Park, D.-K. Kim, B. Nedumaran, W. G. Jang, W.-J. Cho, J. Ha, I.-K. Lee, et al. Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase-Dependent Regulation of the Orphan Nuclear Receptor SHP Diabetes, February 1, 2008; 57(2): 306 - 314. [Abstract] [Full Text] [PDF]

				S. Uzbekova, Y. Arlot-Bonnemains, J. Dupont, R. Dalbies-Tran, P. Papillier, S. Pennetier, A. Thelie, C. Perreau, P. Mermillod, C. Prigent, et al. Spatio-Temporal Expression Patterns of Aurora Kinases A, B, and C and Cytoplasmic Polyadenylation-Element-Binding Protein in Bovine Oocytes During Meiotic Maturation Biol Reprod, February 1, 2008; 78(2): 218 - 233. [Abstract] [Full Text] [PDF]

				Q. Jin, L. Feng, C. Behrens, B. N. Bekele, I. I. Wistuba, W.-K. Hong, and H.-Y. Lee Implication of AMP-Activated Protein Kinase and Akt-Regulated Survivin in Lung Cancer Chemopreventive Activities of Deguelin Cancer Res., December 15, 2007; 67(24): 11630 - 11639. [Abstract] [Full Text] [PDF]

				V. Venkateswaran, A. Q. Haddad, N. E. Fleshner, R. Fan, L. M. Sugar, R. Nam, L. H. Klotz, and M. Pollak Association of Diet-Induced Hyperinsulinemia With Accelerated Growth of Prostate Cancer (LNCaP) Xenografts J Natl Cancer Inst, December 5, 2007; 99(23): 1793 - 1800. [Abstract] [Full Text] [PDF]

				R. J.O. Dowling, M. Zakikhani, I. G. Fantus, M. Pollak, and N. Sonenberg Metformin Inhibits Mammalian Target of Rapamycin Dependent Translation Initiation in Breast Cancer Cells Cancer Res., November 15, 2007; 67(22): 10804 - 10812. [Abstract] [Full Text] [PDF]

				L. W. Jones, M. J. Haykowsky, J. J. Swartz, P. S. Douglas, and J. R. Mackey Early Breast Cancer Therapy and Cardiovascular Injury J. Am. Coll. Cardiol., October 9, 2007; 50(15): 1435 - 1441. [Abstract] [Full Text] [PDF]

				C. Forcet and M. Billaud Dialogue Between LKB1 and AMPK: A Hot Topic at the Cellular Pole Sci. Signal., September 18, 2007; 2007(404): pe51 - pe51. [Abstract] [Full Text] [PDF]

				M. N Pollak Insulin, insulin-like growth factors, insulin resistance, and neoplasia Am. J. Clinical Nutrition, September 1, 2007; 86(3): 820S - 821S. [Abstract] [Full Text] [PDF]

				S. L. Bowker and J. A. Johnson Prospective Study of Hyperglycemia and Cancer Risk: Response to Stattin et al. Diabetes Care, July 1, 2007; 30(7): e77 - e77. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-06-1500v1 66/21/10269    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zakikhani, M. Articles by Pollak, M. Search for Related Content PubMed PubMed Citation Articles by Zakikhani, M. Articles by Pollak, M.